- Conditions
- Bladder Cancer
- Interventions
- Cysview, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
- Drug · Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1249–1272
of 8,265
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lung Cancer, Precancerous Condition
- Interventions
- iloprost, placebo
- Drug · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Denver, Colorado • Baltimore, Maryland + 3 more
- Conditions
- HIV/AIDS
- Interventions
- Family-Based HIV prevention, Adolescent Only Health Promotion
- Behavioral · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 13 Years to 18 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Cardiovascular Disease
- Interventions
- discharge vs. overnight stay
- Other
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 2
- States / cities
- New York, New York • Dallas, Texas
- Conditions
- Prostate Cancer
- Interventions
- Partner and CDC brochure condition, CDC brochure only condition
- Behavioral
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 231 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Trichomonas Vaginitis, Chlamydia Trachomatis, Neisseria Gonorrhoeae Infection
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 15 Years and older · Female only
- Enrollment
- 305 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome
- Interventions
- Not listed
- Lead sponsor
- Immunovia, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,349 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 13
- States / cities
- Stanford, California • New Haven, Connecticut • Chicago, Illinois + 8 more
- Conditions
- Coronary Artery Disease (CAD), Heart Disease, Coronary Atherosclerosis
- Interventions
- Coronary computed tomography angiography
- Diagnostic Test
- Lead sponsor
- HeartFlow, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Greenwood Village, Colorado
- Conditions
- High-risk Large B-cell Lymphoma (LBCL)
- Interventions
- Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Etoposide, Rituximab, Doxorubicin, Vincristine, Prednisone
- Biological · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 26 more
- Conditions
- Obesity
- Interventions
- Time Restricted Eating (TRE), Caloric Restriction (CR)
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Sars-CoV2, COVID
- Interventions
- Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 257 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 6
- States / cities
- Newark, New Jersey • Bay Shore, New York • Huntington, New York + 3 more
- Conditions
- Childhood Obesity
- Interventions
- Risk-informed obesity care plan
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 2 Years to 12 Years
- Enrollment
- 720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Coronary Artery Disease
- Interventions
- Not listed
- Lead sponsor
- Health Diagnostic Laboratory, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Camp Hill, Pennsylvania • Ephrata, Pennsylvania • Lancaster, Pennsylvania
- Conditions
- Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
- Interventions
- 3.0-T MRI, biopsy
- Device · Procedure
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma, Mantle-Cell Lymphoma, Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
- Interventions
- Busulfan (conditioning for AUTO transplant), Etoposide (conditioning for AUTO transplant), Cyclophosphamide (conditioning for AUTO transplant), Mesna (prior to AUTO transplant), autologous (auto) peripheral blood stem cell transplantation, Neupogen, Fludarabine (conditioning for ALLO Transplant), Busulfan (conditioning for ALLO Transplant), non-myeloablative allogeneic (allo) transplant, Tacrolimus, Sirolimus, Methotrexate
- Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Hypotension, Pressure Ulcer
- Interventions
- Nasal alar oxygen sensor
- Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- COVID, Coronavirus Infection
- Interventions
- Chloroquine, Placebo oral tablet
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Ischemic Stroke; Ischemic Attack, Transient
- Interventions
- Milvexian, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 12,523 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 127
- States / cities
- Mesa, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 102 more
- Conditions
- ASCVD
- Interventions
- Not listed
- Lead sponsor
- Cardiology Consultants of Philadelphia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- Clearwater, Florida • Jacksonville, Florida • Houma, Louisiana + 2 more
- Conditions
- Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID-19 Disease
- Interventions
- INO-4800, CELLECTRA® 2000, Placebo
- Drug · Device
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,307 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 16
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 12 more
- Conditions
- Social Isolation, Depression, Anxiety, Debility
- Interventions
- Not listed
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Type 2 Diabetes Treated With Insulin, Pregnancy, High Risk
- Interventions
- Continuous Glucose Monitor, Routine Capillary Blood Glucose Monitoring (Fingerstick Glucose)
- Device
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Leukemia
- Interventions
- 5-Azacytidine, Lenalidomide
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myelogenous Leukemia AML, Myelodysplastic Syndrome MDS
- Interventions
- Vidaza and Valproic Acid
- Drug
- Lead sponsor
- Patrick Stiff
- Other
- Eligibility
- 2 Years to 89 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 1
- States / cities
- Maywood, Illinois